AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read$AMGN

RBC Capital raises Amgen stock price target on strong earnings beat

RBC Capital raised Amgen's (AMGN) price target to $470, citing strong Q3 earnings. Revenue was $10.37B, beating estimates. Amgen raised full-year revenue and EPS guidance. Analysts revised earnings upwards, with 8 raising targets. AMGN stock is up 40% YTD.

Original reporting
investing.com
Published Nov 4, 2026, 2:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 2:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AMGN
Bullish
high confidence
Mentioned
$AMGN
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The earnings beat and guidance raise are likely to drive short‑term buying interest and support a higher stock price.

02

Market read

Strong earnings and guidance lift make AMGN a notable trade idea for healthcare‑focused investors.

03

What to watch

Potential headwinds from patent expirations and competitive pricing pressures.

Relevance 9/10Novelty 9/10Timing: after-hours

Background

Amgen's Q3 earnings beat expectations and raised guidance, prompting multiple analysts to lift price targets.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

RBC Capital raised its price target to $470 and Amgen reported Q3 revenue beat and raised full-year guidance.

Expected impact

likely upward pressure as investors price in higher revenue and EPS guidance.

Evidence & confidence

Strong product performance, revenue beat, and a $0.40 EPS guidance increase are material for a large‑cap biotech.

Market effects

Sector

Biotech sector may see broader optimism as Amgen's results highlight strong pipeline momentum.

Regional

U.S. markets could see a modest lift in healthcare indices.

Global

Limited to investors tracking large‑cap pharma; no immediate global macro effect.

Counterpoint

What could challenge this read

Some analysts may question sustainability of growth given high valuation multiples.

Key entities

  • analyst
    RBC Capital

    Raised price target to $470 and maintained Outperform rating.

  • company
    Amgen Inc.

    Reported Q3 results, beat revenue, and increased full‑year guidance.

Read at source← All news

StoryAmgen posts Q3 2026 earnings beat and lifts 2026 revenue and EPS outlook

Also covered by

6 outlets

Related articles

NOV 4
$AMGNLow

Amgen starts MariTide autoinjector study as pivotal readouts approach

Amgen (AMGN) is advancing its GLP-1 drug candidate, MariTide, with a new Phase 3 study for autoinjector use, aiming for a 2027 completion. The company expects pivotal Phase 3 data next year, with dosing frequency and tolerability as key focus areas. Amgen plans $2.6B in capital expenditures this year, partly for MariTide manufacturing. Q3 revenues rose 8% to $10.4B, with strong performance from key brands.

biospace.com1 min
NOV 4
$AMGNMed

Amgen stock price target raised to $531 by TD Cowen on growth

TD Cowen raised its price target on Amgen (AMGN) to $531 from $452, citing strong Q3 2026 results and growth prospects. The stock trades near its 52-week high. Amgen's revenue and EPS guidance were increased, driven by products like Uplizna and Imdelltra. Multiple analysts revised earnings upwards, though the stock is slightly overvalued according to InvestingPro.

investing.com2 min
NOV 4
$AMGNMedAI 8/10

Truist raises Amgen stock price target on earnings beat

Truist Securities raised its price target for Amgen (AMGN) to $398 from $380, maintaining a Hold rating. The stock is near its 52-week high after Q3 2026 earnings beat expectations, with revenue of $10.4B and EPS of $6.45. Amgen raised full-year revenue and EPS guidance. Analysts cite strong performance and pipeline potential as key drivers.

investing.com2 min